Simvastatin with or without ezetimibe in familial hypercholesterolemia.

@article{Kastelein2008SimvastatinWO,
  title={Simvastatin with or without ezetimibe in familial hypercholesterolemia.},
  author={J. Kastelein and F. Akdim and E. Stroes and A. Zwinderman and M. Bots and A. Stalenhoef and F. Visseren and E. Sijbrands and M. Trip and E. Stein and D. Gaudet and R. Duivenvoorden and E. Veltri and A. Marais and E. de Groot},
  journal={The New England journal of medicine},
  year={2008},
  volume={358 14},
  pages={
          1431-43
        }
}
BACKGROUND Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode… Expand
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
TLDR
Formal cardiovascular outcome trials are underway and these will provide additional insights into the long-term effects of ezetimibe on clinical events as well as on atherogenic dyslipidaemia, beyond LDL cholesterol levels. Expand
Statin/ezetimibe combination therapy: emerging evidence.
TLDR
The Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis (ARBITER 6-HALTS) study comparing niacin with ezetimibe as an add on to statin therapy showed clear superiority of the former, however, there are methodological reservations regarding both of these trials. Expand
The ENHANCE trial: analysis and clinical significance
TLDR
Despite achieving a significant differential reduction in LDL-C, no regression in carotid intima-media thickness was observed at the end of the 2-year follow-up period and the results of the ongoing outcome trials with ezetimibe are needed to know for certain the effect of ezettimibe on clinical outcomes. Expand
Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial.
TLDR
Combined therapy with fluvastatin 20 mg plus ezetimibe 10 mg daily resulted in a significant improvement in changes in the estimated glomerular filtration rate, and side-effect and safety profiles were similar in the two groups. Expand
Carotid Atherosclerosis Progression in Familial Hypercholesterolemia PatientsClinical Perspective
TLDR
Over the years, intensification of statin therapy in HeFH patients has resulted in an impressive decrease in carotid atherosclerosis progression, and in studies that assess other antiatherosclerotic modalities, statin Therapy may still induce rapid changes in cIMT. Expand
Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
TLDR
Claims that simvastatin may be beneficial in preserving endothelial function in prediabetic subjects with normo- or mild-to-moderate hypercholesterolemia are supported, and a deleterious effect of E-selectin and intravascular cellular adhesion molecule-1 levels that were independent of LDL-C changes are suggested. Expand
Ezetimibe therapy for dyslipidemia: an update.
TLDR
The results of the ongoing IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) which compares ezetimibe plus simVastatin with simvastatin monotherapy with regard to CVD outcomes after acute coronary syndromes should further elucidate the effect of ezETimibe on CVD events. Expand
Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?
TLDR
Whether ezetimibe can add to the benefits of statins on atherosclerosis and cardiovascular risk reduction in relation to further LDL-C lowering and lipid-modifying properties is discussed. Expand
Ezetimibe plus simvastatin for the treatment of hypercholesterolemia
TLDR
The controversy around the role of ezetimibe is broach, particularly in light of the results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), which is the first to demonstrate incremental cardiovascular risk reduction with the addition of eZetIMibe to simvastatin. Expand
[Lower is better: ENHANCE affair].
TLDR
The experience of the ENHANCE trial suggests to pharmaceutical companies, researchers, clinicians, scientific companies and media a deep meditation in order to avoid in the future similar problems in the management of results of medical research. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin.
TLDR
High-dose simvastatin therapy reduces arterial wall IMT in more than two thirds of the patients, with its largest effect on the femoral artery. Expand
Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans
TLDR
Four weeks of simvastatin treatment improves endothelial function independently of LDL cholesterol lowering, at least in part by reducing oxidant stress. Expand
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
TLDR
This study addresses the question of whether a regimen that uses drugs with different mechanisms of action will be of further benefit in terms of atherosclerosis reduction compared to statin monotherapy. Expand
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial
TLDR
The results show that aggressive LDL-cholesterol reduction by atorvastatin was accompanied by regression of carotid intima media thickness in patients with familial hypercholesterolaemia, whereas conventional LDL lowering was not. Expand
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
TLDR
When coadministered with simvastatin, ezetimibe provided significant incremental reductions in LDL-C and TG, as well as increases in HDL-C, comparable to statin alone. Expand
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness
TLDR
Marked LDL reduction (<100 mg/dL) with a high-potency statin provides superior efficacy for atherosclerosis regression at 1 year, suggesting that marked LDL reduction with synthetic statins may provide enhanced reduction in clinical coronary event rates. Expand
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
TLDR
Both placebo- and statin-treated patients with familial hypercholesterolemia are best treated with high-dose atorvastatin, a therapeutic regimen that induces atherosclerosis regression and is safe and well tolerated over a 4-year period. Expand
Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)
TLDR
This is the first randomized trial to show that a low-dose metoprolol CR/XL and fluvastatin can reduce the rate of progression of carotid IMT in clinically healthy, symptom-free subjects with carotids plaque, and suggests that &bgr;-blockers may have a favorable effect on atherosclerosis development. Expand
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
TLDR
In patients with familial hypercholesterolemia, the use of torcetrapib withAtorva statin, as compared with atorvastatin alone, did not result in further reduction of progression of atherosclerosis, as assessed by a combined measure of carotid arterial-wall thickness, and was associated with progression of disease in the common carotids segment. Expand
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins
TLDR
The addition of extended-release niacin to statin therapy slowed the progression of atherosclerosis among individuals with known coronary heart disease and moderately low HDL-C. Expand
...
1
2
3
4
5
...